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Binding Immunoglobulin Protein (BIP) Inhibits TNF-α–
Induced Osteoclast Differentiation and Systemic Bone Loss 
in an Erosive Arthritis Model
Mario M. Zaiss,1 Christopher Hall,2  Neil W. A. McGowan,2 Rebecca Babb,2 Vikesh Devlia,2 Sébastien Lucas,1 
Sajeda Meghji,3 Brian Henderson,3 Aline Bozec,1 Georg Schett,1 Jean-Pierre David,4 Gabriel S. Panayi,2 
Agamemnon E. Grigoriadis,2  and Valerie M. Corrigall2
Objective. The association between inflammation and dysregulated bone remodeling is apparent in rheumatoid 
arthritis and is recapitulated in the human tumor necrosis factor transgenic (hTNFtg) mouse model. We investigated 
whether extracellular binding immunoglobulin protein (BiP) would protect the hTNFtg mouse from both inflammatory 
arthritis as well as extensive systemic bone loss and whether BiP had direct antiosteoclast properties in vitro.
Methods. hTNFtg mice received a single intraperitoneal administration of BiP at onset of arthritis. Clinical disease 
parameters were measured weekly. Bone analysis was performed by microcomputed tomography and histomorpho-
metry. Mouse bone marrow macrophage and human peripheral blood monocyte precursors were used to study the 
direct effect of BiP on osteoclast differentiation and function in vitro. Monocyte and osteoclast signaling was analyzed 
by Western blotting, flow cytometry, and imaging flow cytometry.
Results. BiP-treated mice showed reduced inflammation and cartilage destruction, and histomorphometric analysis 
revealed a decrease in osteoclast number with protection from systemic bone loss. Abrogation of osteoclast function 
was also observed in an ex vivo murine calvarial model. BiP inhibited differentiation of osteoclast precursors and pre-
vented bone resorption by mature osteoclasts in vitro. BiP also induced downregulation of CD115/c-Fms and Receptor 
Activator of NF-κB (RANK) messenger RNA and protein, causing reduced phosphorylation of the p38 mitogen–activated 
protein kinases, extracellular signal–regulated kinases 1/2 and p38, with suppression of essential osteoclast transcrip-
tion factors, c-Fos and NFATc1. BiP directly inhibited TNF-α– or Receptor Activator of NF–κB Ligand (RANKL)–induced 
NF-κB nuclear translocation in THP-1 monocytic cells and preosteoclasts by the canonical and noncanonical pathways.
Conclusion. BiP combines an anti-inflammatory function with antiosteoclast activity, which establishes it as a 
potential novel therapeutic for inflammatory disorders associated with bone loss.
INTRODUCTION
One of the many pathological facets of rheumatoid arthritis 
(RA) is the increased local and systemic loss of bone, leading to joint 
erosions and osteopenia, respectively. In RA, bone loss is exac-
erbated by the excessive production of inflammatory cytokines, 
especially tumor necrosis factor α (TNF-α), in the local environment 
of the inflamed joint, which results in increased osteoclast differenti-
ation and subchondral bone degradation as well as systemic bone 
loss (1,2). The capacity for TNF-α to drive osteoclastogenesis has 
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been amply demonstrated in the human TNF-α transgenic (hTNFtg) 
mouse model. These mice exhibit a rapidly developing, spontane-
ous, destructive arthritis with severe systemic osteopenia recapit-
ulating the pathological features of RA (3). In our previous studies, 
we have demonstrated that binding immunoglobulin protein (BiP; or 
78 kDa glucose-regulated protein [GRP78]), a member of the heat 
shock protein 70 family, has prophylactic and therapeutic properties 
in the murine- collagen-induced arthritis (CIA) model of RA when 
administered systemically as an extracellular protein (4,5). Histolog-
ical analysis of BiP-treated arthritic mice showed complete preser-
vation of the joint architecture with a lack of detectable damage to 
cartilage (4). However, whether BiP had any effects specifically on 
osteoclasts was not investigated. Because a major biomarker for 
extracellular BiP activity is the attenuation of TNF-α activity (6), we 
investigated whether BiP had the potential to rescue the spontane-
ous arthritis in hTNFtg mice, with additional emphasis on the effects 
on osteoclasts both in vivo and in vitro.
Earlier human studies in vitro indicated that the primary effect 
of BiP was through monocytes, skewing their phenotype to that of 
a “deactivated monocyte,” inducing interleukin 10 (IL-10) produc-
tion and inhibiting TNF-α (6). This is pertinent because peripheral 
blood (PB) monocytes represent a precursor population that differ-
entiates into bone-resorbing osteoclasts, dendritic cells (DCs), or 
tissue macrophages, depending on their niches, local cytokine envi-
ronment, and the cell surface receptors expressed (7,8). Indeed, 
we have reported that BiP treatment of PB monocyte–derived DCs 
skewed DC development toward indoleamine 2,3-dioxygenase + 
(IDO+) anti-inflammatory DCs and that direct cell contact between 
BiP-treated IDO+ DC and autologous T cells, in the absence of fur-
ther BiP, led to the induction of cytotoxic T-lymphocyte–associated 
antigen 4 (CTLA-4)+ regulatory T cells (9). In vivo, this may be part 
of the successful therapeutic action seen in the adoptive transfer 
studies in CIA, using mixed lymph node cells and splenocytes taken 
from BiP-treated mice and injected into mice with ongoing CIA. 
Strikingly, these experiments confirmed that the therapeutic action 
of recombinant human BiP in patients with active RA was not reli-
ant on the continued presence of the protein and suggested that 
one mechanism of action of BiP may be to induce differentiation of 
immunoregulatory T cells to correct the immunological imbalance 
induced by inflammation and, ultimately, to restore homeostasis 
(10,11). This modulation of the immune cell subpopulations may 
account for the long-lasting therapeutic effect following a single 
treatment. As BiP is detectable in human sera during both health 
and disease, it may assist in the restoration of homeostasis follow-
ing an acute inflammatory incident. Indeed, in patients with RA, cir-
culating levels of BiP are reduced compared with those of disease 
controls (11), which may explain, in part, why patients with RA have 
ongoing chronic inflammation.
The recognition of the importance of TNF-α in the pathogen-
esis of RA has led to improved therapies (12). However, to reduce 
joint damage and disability, both inflammation and dysregulated 
bone metabolism need to be addressed. TNF inhibitors have a 
considerable therapeutic success in this respect (12). TNF-α is a 
known activator of osteoclasts in inflammatory disease. However, 
although anti-TNF biologics efficiently reduce inflammation, they 
are unable to inhibit systemic bone resorption. Thus, systemic 
bone loss is normally treated by additional antiresorptives, such 
as bisphosphonates. These offer long-lasting protection from 
osteopenia but fail to control any concomitant inflammation and 
may be associated with serious adverse events (13). Therefore, 
the need remains for a novel treatment that delivers long-term 
drug-free relief from systemic bone loss, such as that found in RA.
In this study, a single intraperitoneal injection of BiP, admin-
istered at the onset of spontaneous arthritis in the hTNFtg mouse 
model, significantly alleviated disease by suppressing inflamma-
tion and protecting against bone loss. More importantly, BiP also 
inhibited osteoclast differentiation, which suggests that BiP has 
the unique potential to attenuate both the immunological param-
eters of inflammation as well as abnormal bone resorption. 
These functions suggest that BiP has considerable potential as a 
novel therapeutic in patients with active RA. Indeed, the recently 
completed Phase I/IIa clinical trial in RA patients confirmed that 
BiP was safe and showed some efficacy (10).
MATERIALS AND METHODS
hTNFtg mice. hTNFtg mice (Tg197; genetic background 
C57BL/6) (14) develop a chronic inflammatory and destructive 
polyarthritis within 4 to 6 weeks after birth. A single intraperi-
toneal dose of BiP (10 μg/mouse prepared as described (4)) or 
phosphate-buffered saline (PBS) as vehicle control was injected 
at 5 weeks. Two independent experiments were performed each 
with four mice/group, and similar observations were obtained. All 
animal experiments were performed with the agreement of the 
ethical committee, and they followed local authorities at Erlan-
gen University and the UK Home Office.
Clinical assessment. Assessment of clinical parameters 
of arthritis (paw swelling, grip strength, cartilage degradation) was 
assessed semiquantitatively starting 1 week after initial treatment 
and subsequently at weekly intervals as described previously (15).
Bone histomorphometry and histology. Histomorpho-
metry was performed on sections of the paw or tibia 5 weeks after 
the beginning of the treatment for the hTNFtg mice. Histological 
analyses were performed as described previously (16). All quanti-
fications were performed by digital image analysis (OsteoMetrics) 
using a microscope (Carl Zeiss) equipped with a digital camera.
Microcomputed tomography. Microcomputed tomog-
raphy (μCT) analysis was performed with a μCT40 scanner 
(Scanco) using the following parameters: voltage, 40 kV; X-ray 
current, 250 μA; exposure time, 5000 ms/projection for 720 
projections; matrix, 1024 × 1024; voxel size in reconstructed 
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image, 9 μm. Images were analyzed with Scanco evaluation 
software for the following bone parameters at the metaphysis 
of the proximal tibia: ratio of bone volume to total volume, tra-
becular number, thickness, and separation.
Cell culture. Murine bone marrow cells from 6- to 11-week-
old CD1 mice or C57BL/6 mice were cultured overnight in Alpha 
MEM (MilliporeSigma) containing 10% batch-tested fetal calf 
serum (FCS) and macrophage-colony stimulating factor (M-CSF) 
(50 ng/ml) (R&D Systems). After 24 hours, nonadherent cells 
were harvested and seeded either in culture dishes/plates or on 
dentine slices (3 × 104 cells/6-mm well), and cultured in the pres-
ence of M-CSF (50 ng/ml) for 3 days followed by a further 3 to 4 
days in 25 ng/ml M-CSF and 5 ng/ml RANKL (R&D Systems), in 
the absence or presence of BiP (0.02-20 μg/ml) as indicated. Tar-
trate-resistant acid phosphatase (TRAP) staining for the evalua-
tion of osteoclast differentiation was performed using a leukocyte 
acid phosphatase kit (MilliporeSigma). Osteoclasts were identified 
as TRAP-positive cells with three or more nuclei. All experiments 
were repeated at least 6 times, and similar results were obtained 
in cells derived from both CD1 and C57BL/6 strains of mice.
For human studies, heparinized blood samples from healthy 
controls were collected after fully informed consent (Guy’s Hospital 
Ethical Committee Ref: 01/05/01). PB monocytes were negatively 
selected from PB mononuclear cells (PBMCs) using immunomag-
netic beads (Invitrogen). For differentiation studies, monocyte cul-
tures were seeded into culture dishes or onto dentine discs (5 × 104 
cells/6-mm well) and cultured in M-CSF (50 ng/ml). After 4 days, 
cells were treated with M-CSF (25 ng/ml) and RANKL (10 ng/ml) 
in the absence or presence of the indicated concentration of BiP 
(0.02-20 μg/ml) for up to 10 days more. Osteoclasts were identified 
either by TRAP staining as detailed above, by tetramethylrhodamine 
staining, Phalloidin staining (MilliporeSigma) for F-actin rings, or by 
immunolocalization for the vitronectin receptor (VnR) using the 23c6 
antibody as described previously (17). Resorption pits were quan-
tified following the removal of the cells and staining with Toluidine 
blue. In some experiments, BiP was added to mature osteoclasts 
at day 10 following the addition of RANKL. Resorption pits were 
quantified by image analysis using ImageJ. All experiments were 
repeated at least six times, and similar results were obtained.
THP-1 cells (American Type Culture Collection [ATCC]) 
were grown in RPMI 1640 supplemented with heat-inactivated 
10% FCS and subcultured at 0.5 × 106 cells/ml 24 hours before 
use. Cells were checked for their ability to bind BiP conjugated 
with fluorescein isothiocyanate and expression of RANK prior to 
exposure to BiP. Cells were pretreated for 1 hour with BiP and 
then stimulated with RANKL (50 ng/ml) (R&D Systems) or TNF-α 
(10 ng/ml) (Peprotech) for 10 minutes.
Quantitative reverse transcription polymerase 
chain reaction. Total RNA was isolated using TRIzol (Invitro-
gen). One microgram of total RNA was used for the first-strand 
complementary DNA synthesis (Amersham Biosciences), which 
was then used for SYBR Green–based quantitative reverse 
transcription polymerase chain reaction (RT-PCR) in triplicate 
according to the manufacturer’s instructions. Gene expression 
was normalized to the housekeeping gene β-actin. Specific prim-
ers: cathepsin K: Fwd 5’-ATATGTGGGCCAGGATGAAAGTT-3’; 
Rev 5’-TCGTTCCCCACAGGAATCTCT-3’, c-fms: Fwd 5’-ATGT 
CAAAGATCCGGCCCAC-3’; Rev 5’-GGTCAGTGATCAGACAG 
GGC-3’, RANK: Fwd 5’TGGAACTCAGACTGCGAGTG-3’; Rev 
5’-CCTTGTTGAGCTGCAAGGGA-3’, β-actin: Fwd 5-TGTCCAC 
CTTCCAGCAGATGT-3’; Rev 5’-AGCTCAGTAAC-AGTCCGCCT 
AGA-3’.
Signaling studies and Western blotting. Purified human 
monocytes as above were cultured in the presence of 50 ng/ml 
M-CSF followed by a further 48 hours in the absence or presence 
of 2 μg/ml BiP. Cells were then stimulated with 10 ng/ml RANKL for 
the times indicated, and whole-cell lysates were prepared as pre-
viously described (18). Proteins were transferred to nitrocellulose 
and probed with the phospho-specific extracellular signal–regu-
lated kinases (ERKs) and p38 mitogen–activated protein kinases 
(MAPK) antibodies (Cell Signaling) or with antibodies for the tran-
scription factors c-Fos and NFATc1 (Santa Cruz Biotechnology). 
Equal protein loading was confirmed by blotting with antibodies 
against β-actin or the appropriate total ERK or p38 as indicated. 
Rapidstep-enhanced chemiluminescent reagent (Calbiochem) was 
used for visualization using a ChemiDoc XRS imager (Bio-Rad).
Flow cytometry and imaging flow cytometry. Osteo-
clast precursors were stained for cell surface expression of CD115/
c-Fms (BD Pharmingen) or RANK (Santa Cruz Biotechnology) as 
previously described (6) or for the intracellular presence of NF-κB 
p65 after fixing in 4% paraformaldehyde in immunofluorescence (IF) 
buffer (0.5% bovine serum albumin, 0.01% sodium azide in PBS) 
for 5 minutes at room temperature and solubilizing the cells with 1% 
Triton X-100 in IF buffer. Anti-p65 (Cell Signaling Technology) was 
added for 45 minutes at 4°C, and phycoerythrin-conjugated goat 
anti-mouse IgG antibody (BD Pharmingen) was used as a second-
ary antibody. For NF-κB nuclear translocation, M-CSF–dependent 
osteoclast precursors or THP-1 cells were cultured in the absence 
or presence of BiP (2 μg/ml), for NF-κB p65 translocation, for 1 
hour followed by 10 minutes of treatment with RANKL (10 ng/ml) or 
TNF-α (10 ng/ml) or, for NF-κB p52 translocation, for 4 hours with or 
without BiP (10 μg/ml) and/or RANKL (10 ng/ml). Nuclear transloca-
tion was visualized after staining with specific antibodies against p65 
or p100/p52 (Cell Signaling Technology). Samples were analyzed 
by FACSCalibur (BD Biosciences) using Cellquest Pro software (BD 
Biosciences) or counterstained with 4′,6-diamidino-2-phenylindole 
(DAPI) and analyzed by imaging flow cytometry (Imagestream X) 
using Ideas v.5 software. To visualize p52, nuclear translocation cells 
were viewed using an Eclipse Ni-E inverted microscope (Nikon) at 
×60 magnification and the A1 confocal imaging system (Nikon).
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Murine calvarial bone resorption assay. Bone resorp-
tion was assayed by measurement of calcium release from 5-day-
old murine calvariae in culture (19), with five replicate cultures per 
treatment. After 24 hours, the medium was removed and replaced 
with medium containing RANKL (10 ng/ml) in the absence or 
presence of BiP as indicated. Replicate calvariae were cultured to 
determine the calcium release from unstimulated bone. After 48 
hours, the media were removed and calcium content measured 
by automated colorimetric assay.
Statistical analysis. All statistical analyses were performed 
with Student’s t test (two groups) or with one-way ANOVA fol-
lowed by Tukey’s test (more than two groups) and are represented 
as means ± SEM unless otherwise stated.
Figure 1. Binding immunoglobulin protein (BiP) ameliorates clinical and histological symptoms of arthritis in human tumor necrosis factor 
transgenic (hTNFtg) mice. (A) Clinical parameters, paw swelling, grip strength, and body weight measurements from BiP-treated (+BiP) or 
phosphate-buffered saline–treated (Co) hTNFtg mice (n = 4/group/experiment; data represent results of one out of two independent experiments). 
Histological sections of the tarsal joints of 10-week-old female hTNFtg mice and corresponding quantitative histomorphometric assessment 
of (B, C) synovial inflammation (haemotoxylin and eosin staining), (D, E) cartilage destruction (Toluidine blue staining), and (F, G) osteoclasts 
(tartrate-resistant acid phosphatase [TRAP] staining), osteoclast numbers and bone erosions. *P < 0.05.
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RESULTS
BiP inhibited TNF-α–induced inflammatory arthri-
tis. We first investigated the effects of extracellular recom-
binant BiP on hTNFtg mice that develop spontaneous joint 
inflammation and cartilage destruction typically between 4 and 
6 weeks of age. A single intraperitoneal injection of BiP (10 
μg) in 5-week-old hTNFtg mice ameliorated clinical parame-
ters of disease, with significant decreases in progressive paw 
swelling and a concomitant rescue of grip strength and body 
weight by 10 weeks of age compared with the control (PBS) 
injected mice (Figure 1A). Comparative histological analysis by 
hematoxylin and eosin and Toluidine blue staining as well as 
quantification of the tarsal joints of BiP- or PBS-treated hTN-
Ftg mice revealed significantly decreased inflammation as well 
as decreased cartilage breakdown in the BiP-treated mice 
(Figure 1B-E). This bone-protective effect was associated with 
fewer TRAP-positive osteoclasts in the tarsal joints and an 
overall decrease in the bone erosion area (Figure 1F and G). 
These data indicate that BiP treatment attenuated the param-
eters of inflammatory arthritis, exerted an antiosteoclastogenic 
effect in the affected joints, and preserved joint architecture.
BiP protected from TNF-α–induced systemic bone 
loss. General osteopenia is a characteristic of human RA and is 
also observed in hTNFtg mice (3). TNF-induced systemic bone 
loss was analyzed by assessing the microarchitecture of the 
proximal tibia, which is not directly exposed to the inflamma-
tory environment of the joints. μCT analysis of proximal tibiae 5 
Figure 2. Binding immunoglobulin protein (BiP) protects from tumor necrosis factor (TNF)-mediated systemic bone loss. Structural 
parameters of trabecular bone from the tibiae of 10-week-old BiP- or phosphate-buffered saline–treated human TNF transgenic (hTNFtg) mice. 
(A) Representative micro-computed tomography reconstruction of proximal tibiae from hTNFtg mice treated for 5 weeks in the absence or 
presence of 10 μg BiP showing increased trabecular bone mass in BiP-treated animals. Trabecular bone parameters were quantified for (B) 
bone volume/total volume (BV/TV), trabecular number (Tb.N.), trabecular thickness (Tb.Th.) and trabecular separation (Tb.Sp.). (C) Quantitative 
histomorphometry of osteoclast numbers normalized to trabecular bone perimeter (No.Oc/B.Pm), osteoclast surface normalized to bone 
surface (Oc.S/B.S), and serum levels of C-terminal telopeptide (CTX-1). Data represent means ± SEM (n = 4 animals). *P < 0.05.
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weeks after a single BiP treatment revealed a marked preserva-
tion of bone mass (Figure  2A). Histomorphometric analysis of 
the proximal tibiae confirmed that a single injection of BiP signif-
icantly increased the trabecular bone volume (BV/TV) in hTNFtg 
mice, which was associated with an increased trabecular num-
ber (Tb.N.) and thickness (Tb.Th.) with a concomitant decrease 
in trabecular separation (Tb.Sp.) (Figure 2B). There were no 
significant changes in cortical bone parameters within the time 
frame of these experiments (data not shown).
The overall reduction in the number of osteoclasts observed 
by TRAP staining in the affected paws was also confirmed in the 
proximal tibiae by histomorphometry with a reduction in the num-
ber of osteoclasts per bone perimeter (N.Oc./B.Pm) and osteoclast 
surface per bone surface (Oc.S/B.S) in BiP-treated hTNFtg mice 
compared with control mice (Figure 2C). This correlated well with a 
systemic reduction in serum type I collagen C-terminal telopeptide, 
which is a marker of bone resorption (Figure 2C). Taken together, 
these data suggest that BiP has a therapeutic effect on both sys-
temic and local bone destruction by inhibiting TNF-induced joint 
inflammation as well as osteoclast differentiation and function.
BiP directly suppressed murine and human oste-
oclast formation and function in vitro and ex vivo. The 
previous data showed that BiP treatment decreased osteoclast 
numbers and resorptive activity in both the paw and tibia. This sug-
gested a potential direct effect on osteoclasts, although it was diffi-
cult to assess from the in vivo studies whether this was secondary 
to the established anti-inflammatory properties of BiP. To address 
this, we investigated whether BiP acts directly on osteoclast pre-
cursors or on mature osteoclasts in vitro using murine bone mar-
row and human PBMC-derived osteoclasts. Continuous exposure 
of murine M-CSF–dependent bone marrow–derived osteoclasts to 
BiP caused an inhibition in the number of TRAP-positive osteo-
clasts and expression of the osteoclast marker cathepsin K (Fig-
ure 3A-C). Analysis of the osteoclast resorptive function showed 
that BiP treatment caused a dose-dependent inhibition in the 
percentage of resorbed area on a mineralized dentine substrate 
(Figure  3D). Exposure of human M-CSF–dependent PBMCs to 
BiP similarly caused a dose-dependent inhibition in the forma-
tion of osteoclasts as demonstrated by a decrease in the num-
ber of cells showing the characteristic F-actin ring structure of 
TRAP-positive multinucleated cells as well as a decrease in VnR 
(αvβ3 integrin)-positive cells (Figure 3A and E). The reduction in 
human osteoclast numbers resulted in a concomitant dose-de-
pendent decrease in bone resorption as measured by lacunar 
formation on dentine slices (Figure  3F). To investigate whether 
BiP also acted on cultures enriched in mature osteoclasts, pulse 
experiments were performed in which BiP was added in late-stage 
cultures after osteoclast differentiation had occurred on dentine 
slices. BiP caused a dose-dependent decrease in the number of 
active F-actin ring-positive osteoclasts and inhibited the resorptive 
ability of mature osteoclasts (Figure 3G and H). For independent 
confirmation of the putative direct antiresorptive effects of BiP that 
are independent of inflammation, we used an ex vivo murine cal-
varial resorption model. Addition of BiP to intact calvariae activated 
with RANKL significantly reduced resorption as measured by the 
release of calcium ions into the culture supernatant (Figure  3I). 
Finally, the decrease in osteoclast numbers was not due to cell 
death or apoptosis. Annexin V staining showed that BiP treatment 
did not reduce cell viability, and indeed, cells cultured with BiP were 
less prone to apoptosis than control cells (Figure 3J and K). Taken 
together, these results suggest that BiP suppresses the differen-
tiation of osteoclast precursors as well as the function of mature 
osteoclasts both in vitro as well as ex vivo in a manner that is inde-
pendent of its anti-inflammatory properties.
BiP suppressed osteoclast differentiation signaling 
pathways. To investigate the mechanisms underlying the inhibi-
tion of osteoclastogenesis by BiP, we analyzed specific cytokine 
signaling and downstream signaling pathways known to be 
essential for osteoclast differentiation. Flow cytometric analysis of 
CD115/c-Fms and RANK, the receptors for M-CSF and RANKL, 
respectively, in human PB–derived M-CSF–dependent osteoclast 
precursors revealed that 48-hour treatment with BiP downregu-
lated the expression of CD115 by 63% ± 16% (range of inhibition: 
43% to 79%) (Figure  4A). Similarly, 48-hour treatment with BiP 
inhibited RANK protein expression by 51% ± 29% (range of inhibi-
tion: 22% to 90%) (Figure 4B). The inhibition of c-Fms and RANK 
expression was also observed at the messenger RNA level, as 
quantitative PCR analysis showed significant reductions in c-fms 
and RANK RNA (Figure 4C). To address whether the decrease in 
receptor expression resulted in reduced responsiveness to oste-
oclastogenic cytokines, we analyzed the effect of BiP treatment 
on RANKL-dependent MAPK signaling. Pretreatment of human 
PBMC–derived osteoclast precursors for 48 hours with BiP mark-
edly suppressed RANKL-induced ERK and p38 phosphorylation 
compared with untreated cells (Figure  4D). Further examination 
of RANKL responsiveness in late-stage cultures similarly revealed 
that RANKL-induced pERK levels were also attenuated in cultures 
enriched in mature osteoclasts following BiP treatment (Figure 4E).
BiP suppressed osteoclast transcription factors. We 
next investigated the effect of BiP on the expression of the tran-
scription factors c-Fos and NFATc1, which are essential for oste-
oclast differentiation and lie downstream of RANK and TNF-α 
signaling in osteoclast precursors and monocytes. Preincuba-
tion of human osteoclast precursors with BiP for 48 hours greatly 
reduced the activation of the c-Fos protein following RANKL 
treatment (Figure  4F). RANKL stimulation of NFATc1, a c-Fos 
target gene (20), was similarly blocked in osteoclast precursors 
pretreated with BiP when compared with control cell lysates (Fig-
ure 4F). Mature osteoclast cultures treated with BiP also showed 
a marked decrease in the endogenous expression of both c-Fos 
and NFATc1 transcription factors (Figure 4F).
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Figure 3. Binding immunoglobulin protein (BiP) specifically inhibits murine and human osteoclast formation and activity. (A) Representative 
images of the effects of continuous BiP (2 μg/ml) treatment on murine and human osteoclast differentiation as indicated. Osteoclasts are 
identified by staining for tartrate-resistant acid phosphatase (TRAP) activity, F-actin ring formation following phalloidin staining, and expression of 
vitronectin receptor (VnR; αvβ3 integrin) by immunocytochemistry using the specific 23C6 antibody. Phalloidin and VnR staining was performed 
on osteoclasts cultured on dentine slices. Quantification of the number of murine TRAP + ve cells (B) and quantitative polymerase chain reaction 
analysis of cathepsin K expression (C) following BiP (2 μg/ml) treatment. (D) Dose-response analysis of murine osteoclast resorption following 
BiP treatment. (E) Dose-dependent effects of BiP on the number of F-actin ring-positive human osteoclasts cultured on dentine; *P < 0.007, 
and corresponding resorptive activity (F) *P < 0.004, when BiP was added continuously from the start of culture (osteoclast precursors). (G) 
Dose effects of BiP on the number of F-actin ring-positive human osteoclasts; *P < 0.02, and (H) corresponding resorptive activity; *P < 0.04, 
when BiP was added to late-stage cultures enriched with mature osteoclasts. (I) Ca2+ release representing resorption from intact murine calvarial 
bones cultured in the presence of receptor activator of NF-κb ligand (RANKL) (10 ng/ml) and the indicated concentrations of BiP (1-1000 ng/
ml). *P < 0.05. Apoptosis was assessed in control (J) or BiP-treated (K) preosteoclasts by flow cytometry using 7-aminoactinomycin D and 
Annexin V staining, showing a reduction in the % early apoptotic cells (45.2% vs 5.8%). No differences in any in vitro parameters were observed 
between male and female donors/mice.
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Whether BiP could similarly inhibit TNF-α–induced NF-κB 
signaling, which is also essential for osteoclastogenesis, was 
investigated next in human monocyte–derived osteoclast pre-
cursors as well as in the monocyte cell line THP-1, which shows 
TNF responsiveness. Imaging flow cytometry demonstrated 
that 1 hour of BiP treatment inhibited the TNF-α–induced 
nuclear translocation of p65 NF-κB in both osteoclast precur-
sors and THP-1 cells (Figure  5A and B). Similar results were 
obtained in response to RANKL stimulation (data not shown). 
Because RANKL also stimulates cells via the noncanonical 
Figure 4. Binding immunoglobulin protein (BiP) downregulates CD115 and receptor activator of NF-κb (RANK) cell surface expression and 
downstream signaling in human osteoclast precursors. Flow cytometry analysis of expression of CD115/c-FMS (A) and RANK (B) protein levels 
by macrophage-colony stimulating factor (M-CSF)-dependent human osteoclast precursors cultured in the absence or presence of BiP (2 μg/
ml) for 48 hours. Representative samples showing mean fluorescence intensity: dotted line-negative isotype control; heavy solid line; control-BiP 
treatment; light solid line: +BiP (n = 4). (C) Quantitative polymerase chain reaction analysis of c-fms and RANK expression following 48-hour 
treatment of murine M-CSF–dependent osteoclast precursors with BiP (2 μg/ml). Data show the means ± SEM of duplicate experiments using 
specific primers and normalized to β-actin. *P < 0.05. (D) Western blot analysis showing expression of pERK and pp38 in human osteoclast 
precursors in response to RANK ligand (RANKL) (10 ng/ml) for the indicated times in cells cultured in the absence or presence of BiP (2 μg/ml, 
48h). (E) Expression of RANKL-induced pERK in cultures containing mature human osteoclasts cultured in the absence or presence of BiP (2 
μg/ml, 48 hours). (F) Western blot analysis showing expression of c-Fos and NFATc1 in response to RANKL (10 ng/ml) in osteoclast precursors 
and mature osteoclasts treated in the absence or presence of BiP (2 μg/ml). Total ERK and p38 proteins, and glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) were used as loading controls as indicated. *P < 0.01.
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NF-κB pathway, we investigated the nuclear translocation of 
p52 NF-κB following RANKL stimulation. Confocal microscopy 
and image analyses showed that although RANKL stimulated 
efficient nuclear translocation of p52 in untreated cells, this was 
inhibited by BiP pretreatment (Figure 5C). These results suggest 
that BiP blocks both canonical as well as noncanonical NF-κB 
signaling in monocytes and osteoclast precursors following 
TNF-α and RANKL treatment.
Figure 5. Binding immunoglobulin protein (BiP) inhibits nuclear translocation of NF-κB p65 and p52 in osteoclast precursors and THP-1 
monocytes following TNF-α and RANKL stimulation. M-CSF–dependent (A) human osteoclast precursors or (B) THP-1 cells were pre-treated 
for 1 hour in the absence (Co) or presence of BiP (10 μg/ml) (A, B) and then stimulated with TNF-α (10 ng/ml) for 10 minutes. (C) Preosteoclast 
were cultured in the presence or absence of BiP (10 μg/ml) with or without RANKL (50 ng/ml) for 4 hours. Cells were fixed and processed for 
flow cytometry, imaging flow cytometry, or confocal microscopy as described in the Methods section following staining for NF-κB p65 (A, B) or 
p52 (C) with DAPI counterstain. Panels on the right of each figure section show confocal images of nuclear translocation of p65 and p52 in a 
representative single cell, showing the absence of nuclear translocation in BiP-treated cells. *P < 0.01, n = 3.
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Taken together, these data demonstrate that treatment of 
monocytes and osteoclast precursors with BiP reduces M-CSF– 
and RANKL-induced signal transduction and activation of the 
essential osteoclastogenic transcription factors NF-κB, c-Fos, 
and NFATc1, thereby providing insights into the mechanisms 
whereby BiP could inhibit osteoclast differentiation and resorp-
tive activity in vivo.
DISCUSSION
In this report, we have shown that BiP treatment of hTN-
Ftg mice had extended therapeutic efficacy with protection not 
only from inflammatory arthritis but also bone loss, both sys-
temic and local, following a single administration at the onset 
of disease.
TNF-α is acknowledged as a major driver of disease pathol-
ogy in RA and therefore the ability of anti-TNF agents to protect 
from bone loss has been keenly investigated. It is well-established 
that the immune response has a regulatory role in bone remode-
ling and that uncontrolled chronic inflammation is a critical part of 
disease-induced bone loss (1,21). In addition to RANKL, cytokines 
(TNF-α, IL-6, IL-4, IL-10, and TGF-β) and immune cells (CD4+C-
D25hi and CTLA-4+ regulatory T cells) are complicit in the positive 
and negative regulation of osteoclastogenesis and may act inde-
pendently of RANK/RANKL (22–24). It is clear that although tar-
geting such immune and inflammatory pathways, especially TNF 
signaling, is currently used in the clinic, the reversal of systemic 
bone loss and structural changes in RA by anti-TNF agents alone 
does not appear to prevent osteopenic disorders independently 
of inflammation. As a result, current combination therapies may 
incorporate drugs that specifically target osteoclast activity, such 
bisphosphonates and anti-RANKL (denosumab) (25–29). This 
highlights one important difference between existing therapeutics 
and the mode of action of the immune modulator, BiP, which fulfils 
a dual role by targeting both the inflammatory component of RA as 
well as the systemic bone loss by acting additionally on the oste-
oclast lineage, thus accentuating the novelty of BiP as a potential 
therapeutic.
In vitro studies revealed that BiP can directly inhibit osteo-
clast differentiation. Addition of BiP to preosteoclast cultures 
downregulated two critical cell surface receptors, CD115/c-FMS 
and RANK, although the mechanisms of this inhibition are not yet 
clear. CD115 has already been investigated as a potential target 
for therapy in RA through the use of specific blocking anti-CD115 
monoclonal antibody (30,31). M-CSF/CD115 ligation has been 
shown to upregulate RANK; therefore, the downregulation of 
RANK observed in BiP-treated cultures could be mediated in 
part by decreased M-CSF signaling (32). This was confirmed in 
BiP-treated osteoclast precursor cultures that showed strongly 
suppressed RANKL-induced phosphorylation of ERK and p38 
MAPKs, which would normally be rapidly phosphorylated follow-
ing c-FMS and RANK receptor activation (33). How BiP interferes 
with downstream RANK activation is not yet known, but is likely 
to involve the TRAF family adaptor proteins that are essential for 
mediating RANK-mediated signaling in osteoclasts (34).
The inflammatory cytokine TNF-α induces NF-κB activation 
and thereby augments the production of other proinflammatory 
cytokines, which also act through NF-κB. Both the canonical and 
noncanonical pathways lead to NF-κB translocation and have a 
degree of redundancy, counterregulation, and ligand selectivity. 
Both TNF-α and RANKL can act via the classical canonical path-
way, allowing nuclear translocation of NF-κB p65. Additionally, 
RANKL can act via the noncanonical route, which is driven by 
ubiquitination and processing of the cytoplasmic inhibitor NF-κB 
p100 to form NF-κB p52 (34). Strikingly, we observed that BiP 
inhibited nuclear translocation of NF-κB by both these pathways 
in response to both TNF-α and RANKL. Together with the already 
known anti-inflammatory properties of extracellular BiP, this may 
explain the long-lasting effects of BiP on TNF-α–driven pathol-
ogy. The inhibition of the essential osteoclast transcription factors 
c-Fos and NFATc1 also confirm that the inhibitory effects of BiP 
are manifested across the entire signal transduction cascade 
that drives osteoclastogenesis. The direct osteoclast inhibitory 
functions of BiP in vitro were manifest at two levels, inhibition of 
osteoclast precursors as well as mature osteoclasts characterized 
by inhibition of F-actin rings and/or expression of the osteoclast 
markers TRAP, VnR, and cathepsin K.
Taken together, these results predict that BiP will have ther-
apeutic value in human localized and systemic osteolytic disease 
because of its dual action on mature osteoclast function and dif-
ferentiation in addition to its anti-inflammatory properties. Whether 
BiP can inhibit osteoclasts independently of its anti-inflammatory 
effects is an interesting issue that is yet to be resolved as it may be 
context dependent. One possible candidate for mediating an indi-
rect effect of BiP on osteoclasts in vivo might be IL-10, which is 
an established osteoclast inhibitory cytokine and which we have 
shown to be stimulated by BiP in PBMCs in vitro (6). However, 
our data show unequivocally that BiP has direct effects on osteo-
clast precursors and mature osteoclasts in vitro and also inhibits 
osteoclastic resorption in ex vivo calvarial organ culture, which 
is a noninflammatory model. Therefore, it is tempting to specu-
late that BiP might indeed have direct effects on osteoclasts that 
are separate from its anti-inflammatory effects; however, we have 
not yet demonstrated direct effects of BiP on osteoclasts in our 
study as the hTNFtg in vivo model is not able to separate the two 
processes. Indeed, it remains of prime importance to investigate 
whether BiP has independent effects on the osteoclast lineage 
in vivo in view of the current notion that there are molecular dif-
ferences between subsets of osteoclasts associated with either 
normal bone resorption/turnover or those associated with differ-
ent pathologies, such as RA or even cancer-induced bone loss 
(35–38). Nevertheless, as regards RA and the hTNFtg model in 
our study, whether BiP is acting directly or indirectly on osteo-
clasts does not diminish its potential as a novel therapeutic.
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How BiP affects its target cell populations remains to be 
determined as a putative receptor for BiP has not yet been iden-
tified. Interestingly, as BiP belongs to the heat shock protein 70 
(HSP70) family and shows a 60% to 70% homology with this mol-
ecule, it does not bind any of the multiple receptors identified for 
HSP70 (11). This adds weight to the fact that although HSP70 
extracellular activity tends to be proinflammatory, BiP has pro-
found anti-inflammatory effects.
As a stress protein, endogenous intracellular BiP is upreg-
ulated during cell stress and associated with antiapoptotic and 
cell-protective functions (39). However, these properties of the 
intracellular protein are strikingly different from those of cell-free 
BiP. Thus, BiP has been defined as a moonlighting protein, with 
protein in the intracellular or extracellular compartments having 
distinct and disparate functions (40). This was evident in our 
previous studies, which indicated there was no advantage to 
delivering exogenous BiP at the focus of inflammation, where 
BiP is already overexpressed (41). Rather, a systemic delivery 
that allowed readjustment of the immune system with upreg-
ulation of anti-inflammatory cytokines (6) and induction and 
expansion of regulatory T cells and tolerogenic DCs (9,11) is 
preferred. These changes underlie the ability of BiP to modulate 
the immune response, thus providing potentially well-tolerated 
and long-term therapy (11,42,43). In contrast, manipulation 
of the grp78 gene revealed that inflammation increased with 
greater endogenous BiP production, possibly caused by the 
antiapoptotic function of intracellular BiP (44). Similarly, in a 
murine model of osteoporosis, Hino et al showed that inducing 
endogenous BiP protected against declining bone production, 
which they attributed to effects on osteoblasts; however, they 
did not explore the effect on osteoclast differentiation or func-
tion (45). In contrast, our studies show that extracellular BiP 
clearly provides significant anti-inflammatory and antiresorp-
tive effects even under the unnatural conditions of excessive 
TNF-α production, such as in the hTNFtg mouse.
RA patients have reduced levels of circulating BiP (11), 
which may explain, in part, why patients with RA have ongoing 
chronic inflammation. Using the hTNFtg spontaneous model of 
arthritis in vivo, combined with in vitro effects on osteoclasts, our 
data clearly demonstrate that BiP has additive, likely synergistic, 
anti-inflammatory, and antiosteoclast activity. In the recent Phase 
I/IIA clinical trial in RA, BiP was shown to be safe and well toler-
ated, and biomarker analysis showed considerable anti-inflam-
matory activity with clinical benefit (10). Whether this extends to 
protection from bone loss in RA will be examined in the Phase 
IIB clinical trial.
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